Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (191-200 of 791) with videos related to

Pageof 80
Sort By:
Cancer Science|May 23, 2007
Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406Jingxuan Pan, Alfonso Quintás-Cardama, Taghi Manshouri, et al.
Leukemia Research|April 6, 2012
Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosisAlfonso Quintás-Cardama, Hagop Kantarjian, Zeev Estrov, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 19, 2012
Epstein-Barr virus-induced CD30-positive diffuse large B-cell lymphoma in a patient with mixed-phenotypic leukemia treated with clofarabinePavan Kumar Bhamidipati, Elias Jabbour, Sergej Konoplev, et al.
Expert Review of Anticancer Therapy|March 13, 2015
The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemiaDavid S Sanford, Hagop Kantarjian, Susan O'Brien, et al.
Cancer|September 2, 2006
Novel approaches in the treatment of systemic mastocytosisAlfonso Quintas-Cardama, Ahmed Aribi, Jorge Cortes, et al.
Blood|September 23, 2006
MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutationFrancis J Giles, Jorge Cortes, Dan Jones, et al.
Journal of Clinical Pharmacology|November 27, 2019
Population Pharmacokinetics of Glasdegib in Patients With Advanced Hematologic Malignancies and Solid TumorsSwan Lin, Naveed Shaik, Giovanni Martinelli, et al.
Acta Haematologica|April 1, 2009
BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitorsWanlong Ma, Hagop Kantarjian, Chen-Hsiung Yeh, et al.
Leukemia Research|May 4, 2004
Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemiaPatricia Ault, Hagop Kantarjian, Mary Alma Welch, et al.
International Journal of Hematology|September 4, 2009
Cytogenetic abnormalities in essential thrombocythemia at presentation and transformationMatjaz Sever, Hagop Kantarjian, Sherry Pierce, et al.
Pageof 80

Showing results (191-200 of 791) with videos related to

Sort By:
Pageof 80
Cancer Science|May 23, 2007
Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406Jingxuan Pan, Alfonso Quintás-Cardama, Taghi Manshouri, et al.
Leukemia Research|April 6, 2012
Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosisAlfonso Quintás-Cardama, Hagop Kantarjian, Zeev Estrov, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 19, 2012
Epstein-Barr virus-induced CD30-positive diffuse large B-cell lymphoma in a patient with mixed-phenotypic leukemia treated with clofarabinePavan Kumar Bhamidipati, Elias Jabbour, Sergej Konoplev, et al.
Expert Review of Anticancer Therapy|March 13, 2015
The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemiaDavid S Sanford, Hagop Kantarjian, Susan O'Brien, et al.
Cancer|September 2, 2006
Novel approaches in the treatment of systemic mastocytosisAlfonso Quintas-Cardama, Ahmed Aribi, Jorge Cortes, et al.
Blood|September 23, 2006
MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutationFrancis J Giles, Jorge Cortes, Dan Jones, et al.
Journal of Clinical Pharmacology|November 27, 2019
Population Pharmacokinetics of Glasdegib in Patients With Advanced Hematologic Malignancies and Solid TumorsSwan Lin, Naveed Shaik, Giovanni Martinelli, et al.
Acta Haematologica|April 1, 2009
BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitorsWanlong Ma, Hagop Kantarjian, Chen-Hsiung Yeh, et al.
Leukemia Research|May 4, 2004
Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemiaPatricia Ault, Hagop Kantarjian, Mary Alma Welch, et al.
International Journal of Hematology|September 4, 2009
Cytogenetic abnormalities in essential thrombocythemia at presentation and transformationMatjaz Sever, Hagop Kantarjian, Sherry Pierce, et al.
Pageof 80